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Abstract
Aim: Abnormal hypermethylation of CpG islands as-
sociated with tumor suppressor genes can lead to tran-
scriptional silencing in neoplasia. The aim of this
study was to investigate the promoter methylation and
expression of E-cadherin gene in gastric cardiac ade-
nocarcinoma (GCA).
Methods: A nested MSP approach, immunohistochem-
istry method and RT-PCR were used respectively to
examine the methylation status of the 5' CpG island
of E-cadherin, its protein expression and mRNA ex-
pression in tumors and corresponding normal tissues.
Results: E-cadherin was methylated in 63 of 92 (68.5%)
tumor specimens, which was significantly higher than
that in corresponding normal tissues (P<0.001).
Methylation frequencies of stage III and IV tumor tis-
sues was significantly higher than that in stage I and II
tumor tissues (P = 0.01). Methylation status of poor
differentiation group was significantly higher than
moderate and poor-moderate differentiation groups
(P<0.01). By immunostaining 51 of 92 tumor tisssues
demonstrated heterogeneous, positive immunostaining
of tumor tissues (44.6%), significantly different from
matched normal tissues (P<0.001). Positive immunos-
taining of stage III and IV tumor tissues was signifi-
cantly lower than stage I and II tumor tissues
(P<0.01). Poor differentiation group was also signifi-
cantly lower than moderate and poor-moderate differ-
entiation groups (P<0.05). 80 percent of tumor tissues
with E-cadherin gene methylated showed inactivated
mRNA expression.
Conclusions: High methylation status of the 5' CpG is-
land of E-cadherin gene may be one of the mecha-
nisms in the development of gastric cardiac adenocar-
cinoma.
Key words: E-cadherin; methylation; gastric cardiac
adenocarcinoma
INTRODUCTION
E-cadherin is a Mr 120,000 transmembrane glycopro-
tein expressed on epithelial cells and is responsible for
homophilic, Ca2+-dependent intercellular adhesion
that is essential for the maintenance of normal tissue
architecture in epithelial tissues [1]. The cytoplasmic
domain of E-cadherin binds to α-, β-, and γ-catenins,
which are in turn linked to actins, and this interaction
is critical for its function [2]. Cell-cell and cell-matrix
interactions are crucially involved in neoplastic trans-
formation and metastasis [3, 4]. Defective cell adhe-
sion may contribute to loss of contact inhibition of
growth and loss of cell adhesion may account for the
ability of cancer cells to cross normal tissue bound-
aries and metastasis [5]. The importance of E-cad-
herin in maintaining cell adhesion implies that its dys-
function may play an important role in tumorigenesis.
Loss of E-cadherin expression occurs in a variety of
human tumors and is hypothesized to be an important
step in the progression from tumor formation to inva-
sion and metastasis [6].
In recent years, there are several studies on the criti-
cal role of E-cadherin in tumorigenesis. It has been
shown that germ-line mutations of the E-cadherin
gene is related to familial gastric and colorectal cancer
[7, 8]. Furthermore, somatic mutations of E-cadherin
were also found in gastric carcinoma and allelic loss of
the E-cadherin locus at 16q22.1 has been reported in
different epithelial tumors such as breast, ovarian, en-
dometrial, and prostate carcinomas [9, 10]. Except for
this genetic alterations, epigenetic alteration include
hypermethylation of the 5' CpG island within the pro-
moter of E-cadherin is also responsible for transcrip-
tional repression of the gene [11]. It is known that ab-
normal hypermethylation of CpG islands associated
with tumor suppressor genes can lead to transcription-
al silencing in neoplasia [12]. Indeed, methylation-as-
sociated silencing of E-cadherin represents the most
common cause for its inactivation in several cancers
such as liver, prostate, breast and esophageal [13-15].
Gastric cardiac adenocarcinoma (GCA), which was
formerly registered as esophageal cancer or gastric
cancer, has been diagnosed independently in very re-
cent years, due to the improvement in early endoscop-
ic screening and pathologic diagnosis. China is a coun-
try with high incidence regions of GCA, Especially in
Taihang mountain of North China. Exogenous factors
including nutrition deficiency, unhealthy living habits,
consumption of alcohol and tobacco, pathogenic in-
fections are generally considered as the risk factors for
developing GCA in China [16-18]. However, only a
subset of individuals exposed to the above listed ex-
ogenous risk factors would develop GCA, suggesting
that multiple genetic and epigenetic events may con-
tribute to the progression of GCA. It is now increas-
ingly recognized that epigenetic silencing of gene ex-
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portant alternative mechanism in inactivating tumour
suppressor genes and tumour associated genes in can-
cers [19]. Mutations of the E-cadherin gene are rare in
GCA, thus, in this study, we evaluated the role of
methylation of the 5' CpG island of E-cadherin and




Tumor and paired normal tissue specimens were ob-
tained from 92 patients. These tissues were divided
into two parallel parts, one part was frozen and stored
at -80ﾰC until RNA was extracted, the other part was
formalin-fixed and paraffin-embedded. The cases were
all inpatients for surgical treatment in the Fourth Affili-
ated Hospital, Hebei Medical University between 2004
and 2006. Histological tumor typing was carried out on
the basis of resected specimens in the Department of
Pathology of the same hospital. All gastric cardiac car-
cinomas were adenocarcinomas with their epicenters at
the gastroesophageal junction, i.e. from 1cm above un-
til 2 cm below the junction between the end of the
tubular esophagus and the beginning of the saccular
stomach [20]. Information on TNM staging was avail-
able from hospital recordings and pathological diagno-
sis. The study was approved by the Ethics Committee
of Hebei Cancer Institute and informed consent was
obtained from all recruited subjects.
METHYLATION SPECIFIC POLYMERASE CHAIN
REACTION (MSP) FOR E-CADHERIN PROMOTER
METHYLATION
Genomic DNA from gastric cardiac adenocarcinomas
and adjacent nonmalignant sections was isolated from
paraffin-embedded tissue slides by standard methods
using a simplified proteinase K digestion method. To
examine the DNA methylation patterns, we treated ge-
nomic DNA with sodium bisulfite, as described previ-
ously [21]. In brief, 2 ﾵg of DNA were denatured with
2M NaOH at 37ﾰC for 10 minutes, followed by incu-
bation with 3M sodium bisulphite, pH5.0, at 50ﾰC for
16 hours. Bisulphite treated DNA was then purified
(DNA Cleanup Kit; Promega, Madison, Wisconsin,
USA), incubated with 3M NaOH at room temperature
for five minutes, precipitated with 10M ammonium ac-
etate and 100% ethanol, washed with 70% ethanol,
and resuspended in 20 ﾵl of distilled water.
A nested PCR approach was used to determine the
methylation status within the E-cadherin CpG island in
Exon 1 (sequence -126 bp to +144 bp relative to tran-
scription start, GenBank accession number D49685)
that has been published previously [15]. In the first
round of PCR, 100 ng of bisulfite-treated DNA were
amplified. The sequencing primers were 5'-GTTTA
GTTTTGGGGAGGGGTT-3' (sense) and 5'-ACTAC
TACTCCAAAAACCCATAACTAA-3' (antisense), and
the cycling conditions were one cycle of 95ﾰC for 5
min, followed by 30 cycles of 95ﾰC for 30 s, 50ﾰC for
30 s, 72ﾰC for 30 s, and a final extension at 72ﾰC for
5min. The size of the product after this initial PCR re-
action was 270 bp. For the second round of PCR, this
product was diluted 1:50 in water, and 2 ﾵl of the dilu-
tion were used for MSP. Nested primer sequences for
E-cadherin for the methylated reaction were 5'-TG
TAGTTACGTATTTATTTTTAGTGGCGTC-3'
(sense) and 5'-CGAATACGATCGAATCGAACCG-3'
(antisense), and primer sequences for the unmethylated
reaction were 5'-TGGTTGTAGTTATGTATTTATT
TTTAGTGGTGTT-3' (sense) and 5'-ACACCAAATA
CAATCAAATCAAACCAAA-3' (antisense). PCR pa-
rameters were as listed above, except that the annealing
temperatures for the methylated and unmethylated re-
actions were 64ﾰC and 62ﾰC, respectively. The product
sizes of the methylated and unmethylated reactions
were 112 and 120 bp, respectively. The breast cancer
cell line MB-MDA-231, which demonstrates methyla-
tion and silencing of E-cadherin and reagent blanks
were used as positive and negative controls.
IMMUNOHISTOCHEMICAL STAINING FOR E-CADHERIN
E-cadherin expression was determined by immuno-
staining using the avidin-biotin complex immunoperox-
idase method, which was performed on parallel histo-
pathological sections from paraffin-embedded tumor
section and paired normal tissue. Endogenous peroxi-
dase was blocked with 3% hydrogen peroxide for 10
minutes, followed by microwave antigen retrieval for
nine minutes at 98ﾰC in 10mM sodium citrate buffer
(pH 6.0) and incubated in 2% normal horse serum to
minimize non-specific binding. The slides were sequen-
tially incubated with primary monoclonal, mouse anti-
E-cadherin antibody (1:100 dilution in phosphate
buffered saline, Santa cruz, sc-8426) overnight at 4ﾰC,
biotinylated secondary antibody for 30 min at 37ﾰC and
ABC reagent for 45 min at 37ﾰC. 0.5% 3,3'-Di-
aminobenzidine (Sigma, St Louis, MO) was used as the
chromagen. For a negative control, the primary anti-
body was replaced with mouse IgG. Slides with normal
gastric mucosa were used as a positive control.
MEASUREMENT OF MRNA EXPRESSION
OF E-CADHERIN
RNA was extracted from frozen section tissues by
standard methods using Trizol (Invitrogen, USA).
cDNA was synthesized using the Advantage RT-for-
PCR kit (Clontech, Palo Alto, CA) with oligo (dT)
priming as recommended in the protocol provided.
The GAPDH gene was used as a control. Primer se-
quences of E-cadherin were 5ﾰ‰-CGACCCAACC
CAAGAATCTA-3ﾰ‰(sense) and 5ﾰ‰- AATGGCAG
GAATTTGCAATC-3ﾰ‰(antisense), primer sequence
of GAPDH were 5ﾰ‰-GGGAAACTGTGGCGT
GAT-3ﾰ‰(sense) and 5ﾰ‰-GTGGTCGTTGAGGG
CAAT-3ﾰ‰(antisense), product size were 202bp and
342bp, respectively. PCR products were resolved on
2% agarose gels and signal intensities were quantified
using a computer imaging system. The levels of gene
transcripts were quantified as the ratio of the intensity
of the E-cadherin signal to the intensity of β-actin.
Inactivated expression was scored when expression of
an E-cadherin gene in the tumor sample was <25% of
its expression in the corresponding normal sample.
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Statistical analysis was performed using SPSS10.0 soft-
ware package (SPSS Company, Chicago, Illinois, USA).
Fisher’s exact test and Chi-square test were used to as-
sess statistical significance of differences and compare
categorical associations. Two-sided tests were used to
determine significance, and P values less than 0.05




As shown in Table 1, 92 GCA patients were obtained
in this research, including 73 male and 19 female, age
ranged from 38~76, mean age 56.9. All of the cases
were classified into 4 tumor-node-metastasis (TNM)
stages according to UICC standard, 8 of stage I
(8.7%), 32 of stage II (34.8%), 38 of stage III (41.3%),
14 of stage IV (15.2%). According to the pathological
phases, the cases were classified into 3 groups, 42
(45.7%) of moderate group, 34 (36.9%) of poor-mod-
erate group and 16 (17.4%) of poor group.
METHYLATION ANALYSIS OF E-CADHERIN GENE
The methylation analysis was successfully performed in
all tumor and paired normal tissue specimens (Fig. 1).
For 10% of samples, methylation analysis was repeated
for quality control. In 63 (68.5%) of 92 GCA tumors
E-cadherin methylation was detected, while only in 10
(10.9%) of paired normal tissues E-cadherin methyla-
tion was detected. The frequency of E-cadherin
methylation of tumor tissues was significantly higher
than paired normal tissues (P<0.001). When stratified
for TNM stages, Frequency of E-cadherin gene methy-
lation of GCA patients with stage III and stage IV
(78.8%) were significantly higher than GCA patients
with stage I and stage II (55%) (χ2 = 5.96, P = 0.01).
When stratified for pathological stages, the E-cadherin
gene methylation frequencies of moderate, poor-mod-
erate and poor group were 52.4%, 73.5% and 100%,
frequency of E-cadherin gene methylation of poor
group significantly higher than that in moderate and
poor-moderate groups (χ2 = 8.92, P = 0.003) (Table 2).
IMMUNOSTAINING OF E-CADHERIN GENE
As shown in Table 2, the staining was heterogeneous
in 51 tumor tissues, tumor cells with decreased mem-
branous E-cadherin staining were mixed with tumor
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Fig. 1. Methylation analysis of E-cadherin in tumor tissue (T)
and corresponding normal tissue (N). u: indicates the pres-
ence of unmethylated genes; m: indicates the presence of
methylated genes. Cases 1 and 2: tumor-specific methylation;
Case 3: the tumor is fully methylated, whereas the corre-
sponding normal tissue has a very faint band demonstrating
methylation; Case 4: both of tumor and corresponding nor-
mal tissue unmethylated.
Case 1 Case 2 Case 3 Case 4
NT NT NT NT
mu mu mumu mumu mum u
Table 2. E-cadherin methylation and immunohistochemical staining characteristics of GCA patients.
Group methylation status P Immunohistochemical staining P
MU - +
TNM stage
I4 4 2 6
II 18 14 13 9
III 29 9 26 12
IV 12 2 0.015a 10 4 0.002a
Pathological differentiation of tumor
moderate 22 20 20 2
poor-moderate 25 9 18 16
poor 16 0 0.003b 13 3 0.022b
a P value of stage III and IV patients against stage I and II patients, b P value of poor differentiation group against moderate and
poor-moderate groups
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Frequency of protein expression was 44.6% in tumor
tissues, while paired normal tissue specimens all
demonstrated diffuse strong membranous E-cadherin
staining. Frequency of protein expression was signifi-
cantly different between tumor and paired normal tis-
sues (P<0.001). When stratified for TNM stages, Fre-
quency of E-cadherin gene protein expression of
stage III and IV tumor tissues (30.8%) was significant-
ly lower than that in stage I and II tumor tissues
(62.5%) (χ2 = 9.21, P = 0.002). Frequency of E-cad-
herin gene protein expression of poor group signifi-
cantly lower than that in moderate and poor-moderate
groups (χ2 = 5.23, P = 0.022).
mRNA EXPRESSION FOR THE E-CADHERIN GENE
Levels of the transcripts were determined in the 32 se-
lected frozen GCA samples by RT-PCR analysis (Fig.
3). The 32 GCA samples including 2 of stage I, 2 of
stage II, 8 of stage III and 8 of stage IV of cases in
which the tumor was methylated and 12 cases (2 of
stage I, 4 of stages II, 4 of stage III and 2 of stage IV)
with unmethylated E-cadherin gene. A 202bp fragment
of the E-cadherin gene transcript was generated, with
a 342bp GAPDH fragment of the transcript as a con-
trol. 16 (1 of stage II, 7 of stage III and 8 of stage IV)
cases (80%) of inactivated mRNA expression were ob-
served in 20 tumor samples with E-cadherin gene
methylated, the other 4 (2 of stage I, 1 of stage II, 1 of
stage III) cases showed positive expression. 12 tumor
samples with E-cadherin gene unmethylated all showed
positive expression of E-cadherin gene.
DISCUSSION
China is a country with high incidence of digestive
tract cancer which including esophageal carcinoma,
gastric cancer and gastric cardiac adenocarcinoma
(GCA). GCA, which was formerly registered as
esophageal cancer or gastric cancer, has been diag-
nosed independently in very recent years, due to the
improvement in early endoscopic screening and patho-
logic diagnosis. It has been suggested by several epi-
demiological data that the incidence of GCA is in-
creasing in recent years. Some research has shown that
the mechanism and clinical symptom of GCA is dif-
ferent from gastric cancer but similar to esophageal
cancer. The exact mechanism of the occurrence of
GCA remains unclear for the moment. It is generally
accepted that the hereditary factor that irritating the
occurrence of tumor including two mechanism, genet-
ics and epigenetics mechanism. Genetic abnormalities
of proto-oncogenes and tumor suppressor genes are
well-known changes that are frequently involved in
cancer pathogenesis. However, Epigenetic inactivation
of certain tumor suppressor genes by aberrant pro-
moter methylation is frequently observed in several
cancers and may play a pivotal role in tumorigenesis.
While genetic abnormalities are associated with
changes in DNA sequence, epigenetic events may lead
to changes in gene expression that occur without
changes in DNA sequence. If tumor suppressor genes
are affected, it results usually in transcriptional silenc-
ing and, hence, inactivation of that gene. It may then
confer growth advantages to these cells that favor can-
cer development [22].
As a member of cell adhesion molecular, E-cad-
herin play an important role in maintaining cell adhe-
sion and its dysfunction may result in tumorigenesis.6
The biological consequences of its dysfunction include
disruption of intercellular adhesion and impairment of
￟-catenin-mediated transactivation [23]. To date, how-
ever, the regulatory mechanisms responsible for altered
levels of E-cadherin proteins in GCA have not been
elucidated. It has been reported that hypermethylation
of E-cadherin were associated with gastric cancer and
esophageal adenocarcinoma [21, 24]. However, there
are no other report about the relationship between E-
cadherin methylation and tumorigenesis of GCA. In
this study, we showed that hypermethylation of the 5'
CpG island of the E-cadherin promoter occured fre-
quently in GCA tissues (68.5%)and that this methyla-
tion change was associated with reduced expression of
E-cadherin protein. Our data suggested that epigenetic
silencing of the E-cadherin promoter via hypermethy-
lation may be one of the critical mechanism for inacti-
vation of this gene in GCA. Gene silencing associated
with hypermethylation is mediated by methyl-binding
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Fig. 2. E-cadherin immunostain in
GCA tissue. A: positive staining (nor-
mal tissue). B: negative staining (GCA
tissue).
A (x200) B (x200)
Fig. 3. mRNA analysis of E-cadherin in tumor tissues.
1:100bp DNA marker 2,4,5,6,9: positive mRNA expression
3,7,8: negative mRNA expression.
342bp
202bp
7. Dong:Umbruchvorlage  27.08.2009  13:16 Uhr  Seite 456proteins that bind to methylated cytosines and recruit a
complex of proteins that repress transcription, includ-
ing histone deacetylases [25].
In our study, we found that in the majority of the
cases we examined, E-cadherin methylation was tumor
specific. however, 10 cases in which the methylation
change was present in both tumor and paired normal
tissues from the same patient. Given the sensitivity of
nested MSP, it is possible that normal-appearing speci-
mens contained a rare cancer cell that was unde-
tectable by histomorphology. Due to the limitation of
specimen, we didn’t study the methylation of E-cad-
herin in normal cardia tissues. However, normal
esophageal tissue didn’t show aberrant E-cadherin
methylation in some studies [21] and in previous stud-
ies investigating E-cadherin methylation in different
tumor types, normal tissues from bone marrow, breast,
thyroid,and oral mucosa were unmethylated [14, 26].
These data strongly suggested that the E-cadherin
promoter methylation is an aberrant event. The fact
that we only detected methylation in paired normal tis-
sues from patients in whom the corresponding tumor
was also methylated is consistent with the hypothesis
that the cancer in these individuals arose from a
methylated clonal precursor. In a study of neoplastic
progression in Barrett’s esophagus, hypermethylation
of the tumor suppressor gene p16 was detected in
pathologically normal-appearing specimens obtained
from a patient who later developed dysplasia [27].
Therefore, epigenetic inactivation of tumor suppres-
sor genes may be an early feature of tumorigenesis.
Our results showed that protein expression of E-
cadherin in tumor tissues significantly lower than that
in paired normal tissues, however, immunohistochemi-
cal staining also showed normal membranous staining
of E-cadherin in some tumor samples with E-cadherin
methylation. There are several possible reasons for the
events. First, This was probably due to the fact that
immunohistochemical staining was not as sensitive as
PCR in detecting subpopulations of cells with gene
methylation and hence downregulation of E-cadherin.
Second, tumor tissues may mingle some normal tis-
sues and may showed normal membranous staining of
E-cadherin. Third, gene heterogenic methylation or an
allele methylation may be an important reason. In our
studies, we found that the methylation status of the
tumor tissues that both showed positive protein ex-
pression and hypermethylation were incomplete E-
cadherin methylation. Furthermore, it has been de-
monstrated that DNA methylation which suppressed
gene expression mainly in transcriptional level and the
density of CpG island methylation was related to the
suppressed degree of transcription [28]. Dicky pro-
moter can be completely suppressed by lower density
methylation, however, when promoter was enhanced
by enhanser, function of transcription will be re-
trieved. In our study ,we also found positive mRNA
expression in some tumor samples with E-cadherin
gene methylated. It partly due to the fact that the ex-
tent of promoter methylation was insufficent to sup-
press E-cadherin transcription. In all, Our study sug-
gested that epigenetic silencing of the E-cadherin pro-
moter via hypermethylation may be one of the mecha-
nism for inactivation of E-cadherin in GCA.
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